Search clinical trials for: ABP 959

Total 5427 results

T3D Therapeutics, Inc.
National Institute on Aging (NIA); Alzheimer's Association; Clinilabs, Inc.

Completed

Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

Alzheimer Disease

United States
AbbVie

Terminated

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Alzheimer's Disease

United States
AbbVie

Terminated

Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment

Mild Cognitive Impairment | Alzheimer's Disease

United States
T3D Therapeutics, Inc.

Completed

Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Amgen

Completed

A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH (DAHLIA)

Paroxysmal Nocturnal Hemoglobinuria

Spain, Italy, United States, Norway, Czechia, United Kingdom, Slovenia, Netherlands, Turkey, Portugal, Finland, France, Ireland, Sweden
Medtronic Cardiac Rhythm and Heart Failure

Terminated

Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease

Heart Diseases | Chagas Disease

Colombia, Argentina
IRCCS Eugenio Medea

Recruiting

Pragmatic Abilities in Children With Acquired Brain Injury (ABIabc)

Acquired Brain Injury | Pragmatic Communication Disorder

Italy
3M

Unknown

EXD-959 Orthodontic Brackets and EXD-961 Related Instruments Trial

Malocclusion

United States
University of Wisconsin, Madison

Recruiting

Stress, Inflammation and Immune Response Pilot Study- Aim 3

Inflammation | Systemic Lupus Erythematosus

United States
TYK Medicines, Inc

Recruiting

[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects

Healthy Volunteers

China
Takeda

Completed

A Study of TAK-951 in Healthy Adults

Healthy Volunteers

United States
Takeda

Completed

A Study of TAK-951 in Healthy Adults

Healthy Volunteer

United States
Kyuzi Kamoi

Not yet recruiting

20 Years Results by HBP and DBP in Patients With Type 2 Diabetes Mellitus After Following-up

Diabetes Mellitus
TYK Medicines, Inc

Active, not recruiting

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

NSCLC | Brain Metastases | EGFR Activating Mutation | Leptomeningeal Metastasis

China
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

Postoperative Gastrointestinal Dysfunction

United States, Germany
Millennium Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants

Healthy Volunteers

United States
Akros Pharma Inc.

Completed

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

Anemia of Chronic Kidney Disease

United States
Nagaoka Red Cross Hospital

Unknown

Long-term of 10 Years Results of a Prospective Longitudinal Study

Type 2 Diabetes Mellitus | Blood Pressure

Japan
University of California, Davis
National Institutes of Health (NIH); National Center for Advancing Translational...

Enrolling by invitation

Preductal Oxygen Saturation Target in Term and Late Preterm Neonates With Hypoxemic Respiratory Failure or Pulmonary Hypertension (POST-IT)

Persistent Pulmonary Hypertension of the Newborn | Hypoxemic Respiratory Failure

United States
The Hong Kong Polytechnic University
Tuen Mun Hospital

Recruiting

Program Using a Mobile Application Versus Telephone Advice on Patients at Risk of Coronary Heart Disease : a Pilot RCT

Coronary Heart Disease

Hong Kong
Biogen

Terminated

Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma

Colorectal Cancer | Metastases

United States
Alkermes, Inc.
QPS Netherlands B.V.

Completed

Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly Subjects

Healthy

Netherlands
Palobiofarma SL
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Terminated

Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers

Huntington Disease

Spain
Janssen Inc.

Completed

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (X-PLORE)

Psoriasis

United States, Poland, Canada, Belgium, Germany
AbbVie

Recruiting

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States
Calithera Biosciences, Inc

Terminated

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

Spain, United States, Italy, Canada, France, United Kingdom
Calithera Biosciences, Inc

Completed

A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

Advanced Solid Tumor and Lymphoma Malignancies

United States, Spain, Italy, United Kingdom
Palobiofarma SL
Vall d'Hebron institute of oncology (VHIO), Catalan institute of oncology...

Completed

Study of PBF-999 in Solid Tumour Advanced Cancer

Cancer

Spain
Takeda

Completed

A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954

Renal Impairment | Healthy Volunteers

Czechia, Hungary
Takeda

Completed

A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954

Healthy Volunteers | Hepatic Impairment

Czechia, Slovakia
Life Molecular Imaging SA

Completed

PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations.

Diagnostic Imaging

Singapore
Takeda

Terminated

Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus
Shanghai Fosun Pharmaceutical Industrial Development...

Active, not recruiting

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

Neurofibromatosis 1 | NF1 | Plexiform Neurofibroma

United States, China, Spain
Calithera Biosciences, Inc

Withdrawn

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

Lymphoma, Malignant | Advanced Solid Neoplasms

United States
Calithera Biosciences, Inc

Terminated

A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

Lymphoma, Non-Hodgkin | Lymphoma, Follicular, Marginal Zone

Korea, Republic of, Japan
Calithera Biosciences, Inc

Terminated

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States, Canada
Celltrion

Completed

This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)

SARS-CoV-2 Infection

Korea, Republic of
AbbVie

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

Parkinson's Disease (PD)

United States
TYK Medicines, Inc

Completed

A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation

NSCLC

China
Shanghai Fosun Pharmaceutical Industrial Development...

Recruiting

To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH

Langerhans Cell Histiocytosis | LCH

China
Flare Therapeutics Inc.

Recruiting

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Advanced Solid Tumors Cancer | Advanced Urothelial Carcinoma | Open Label | Oral Drug Administration

United States
Shanghai Fosun Pharmaceutical Industrial Development...

Suspended

MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)

Melanoma

China
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953

Healthy

Japan
Akros Pharma Inc.

Completed

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

Anemia in Chronic Kidney Disease

United States
Calithera Biosciences, Inc

Withdrawn

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

Advanced Solid Neoplasms | Lymphoma Neoplasms
Massachusetts General Hospital
National Comprehensive Cancer Network

Completed

Tivozanib for Recurrent Glioblastoma

Glioblastoma

United States
Invicro

Completed

Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects

Healthy Volunteers

United States
Centocor, Inc.

Completed

A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

Psoriasis

United States
Emory University
AVEO Pharmaceuticals, Inc.

Terminated

Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer

Hepatocellular Cancer

United States
Akros Pharma Inc.

Completed

Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

Anemia of Chronic Kidney Disease

United States

3

Subscribe